Home > Press > NanoMed Pharmaceuticals Hires Chief Scientific Officer
NanoMed Pharmaceuticals, Inc., an early-stage specialty pharmaceutical company dedicated to developing improved therapeutic and diagnostic products to treat or detect cancer and other serious diseases, announced today that it has hired Harry C. Ledebur, Jr., PhD. to serve as the company's Vice President Research & Development, Chief Scientific Officer. Prior to joining NanoMed, Dr. Ledebur was Vice President, Operations & Scientific Affairs for Chromos Molecular Systems, Inc. where he was a member of Chromos' Executive Committee and was responsible for all discovery and product development programs along with quality systems, regulatory affairs and site operations.
NanoMed Pharmaceuticals Hires Chief Scientific Officer
Kalamazoo, MI | Posted on June 21st, 2007
"I am extremely pleased to have the opportunity to partner with a
research and development executive of Harry's caliber," said Stephen
Benoit, NanoMed's President and CEO. "His extensive experience in
preclinical discovery research, product and business development within the
biotechnology and pharmaceutical industries should prove to be a tremendous
asset to NanoMed as we build our drug pipeline and forge strategic product
development relationships," Benoit added. NanoMed's lead product is a
nanoparticle formulation of an FDA-approved cancer drug used to treat
adults diagnosed with acute myeloid leukemia. This lead product is expected
to enter human clinical trials in 2008.
"NanoMed is an exciting company with an innovative nanotechnology
platform for the rapid development of a diversified portfolio of
therapeutic and diagnostic products," said Dr. Ledebur. "I am thrilled to
be joining the NanoMed team and to be given the opportunity to bring
NanoMed's products to market while helping to build a sustainable specialty
pharmaceutical company," Ledebur added.
Previously, Dr. Ledebur was Vice President of Research & Development
and Discovery Programs for Caprion Pharmaceuticals Inc., as well as Program
Head of the Antigen Presenting Cell Program at US-based Valentis, Inc.
(formerly GeneMedicine, Inc.). He began his career at Boehringer Ingelheim
Pharmaceuticals Inc. Dr. Ledebur received his Ph.D. in Molecular & Cell
Biology from Pennsylvania State University and his B.Sc. in Biochemistry
from The Ohio State University.
About NanoMed Pharmaceuticals, Inc.
NanoMed Pharmaceuticals(R), Inc. ( http://www.nanomedpharm.com ) is an
early-stage specialty pharmaceutical company dedicated to developing
improved therapeutic and diagnostic products to treat or detect cancer and
other serious diseases. The company's lead product is a nanoparticle
formulation of an FDA-approved cancer drug used to treat adults diagnosed
with acute myeloid leukemia. This lead product is being developed using
Nanotemplate Engineering(TM), the company's proprietary nanoparticle
manufacturing technology used to formulate small molecules, peptides,
proteins, plasmid DNA, and diagnostic agents. NanoMed is headquartered in
For more information, please click here
President & CEO
NanoMed Pharmaceuticals, Inc.
7107 Elm Valley Drive, Room B1210
Kalamazoo, Michigan 49009 USA
T - (269) 488-8525
F - (269) 488-8544
Copyright © PR Newswire Association LLC.
If you have a comment, please Contact
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
Researchers create vaccine for dust-mite allergies Main Page Content: Vaccine reduced lung inflammation to allergens in lab and animal tests July 22nd, 2014
NIST shows ultrasonically propelled nanorods spin dizzyingly fast July 22nd, 2014
SentiMag® Now Available in Australia and New Zealand July 21st, 2014
More than glitter: Scientists explain how gold nanoparticles easily penetrate cells, making them useful for delivering drugs July 21st, 2014
Harris & Harris Group to Host Conference Call on Second-Quarter 2014 Financial Results on August 15, 2014 July 23rd, 2014
UCF Nanotech Spinout Developing Revolutionary Battery Technology: Power the Next Generation of Electronics with Carbon July 23rd, 2014
Deadline Announced for Registration in 7th Int'l Nanotechnology Festival in Iran July 23rd, 2014
A Crystal Wedding in the Nanocosmos July 23rd, 2014
Organometallics welcomes new editor-in-chief: Paul Chirik, Ph.D. July 22nd, 2014
NSS Pays Tribute to Space Pioneer Frederick I. Ordway III July 7th, 2014
Harris & Harris Group Announces Changes to Its Legal Department June 9th, 2014
SEMATECH Appoints Satyavolu Papa Rao to Lead Process Technology May 13th, 2014